ES2181845T3 - Uso de tomoxetina para el tratamiento de la hiperactividad inducida por trastornos de la atencion. - Google Patents

Uso de tomoxetina para el tratamiento de la hiperactividad inducida por trastornos de la atencion.

Info

Publication number
ES2181845T3
ES2181845T3 ES96300157T ES96300157T ES2181845T3 ES 2181845 T3 ES2181845 T3 ES 2181845T3 ES 96300157 T ES96300157 T ES 96300157T ES 96300157 T ES96300157 T ES 96300157T ES 2181845 T3 ES2181845 T3 ES 2181845T3
Authority
ES
Spain
Prior art keywords
tomoxetine
disorders
care
treatment
hyperactivity induced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96300157T
Other languages
English (en)
Inventor
John Harrison Heiligenstein
Gary Dennis Tollefson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23463572&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2181845(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2181845T3 publication Critical patent/ES2181845T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)

Abstract

LA TOMOXETINA, INHIBIDORA DE LA ABSORCION DE LA NOREPINEFRINA, SE UTILIZA PARA TRATAR LAS ALTERACIONES EN LA CONCENTRACION /HIPERACTIVIDAD.
ES96300157T 1995-01-11 1996-01-09 Uso de tomoxetina para el tratamiento de la hiperactividad inducida por trastornos de la atencion. Expired - Lifetime ES2181845T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/371,341 US5658590A (en) 1995-01-11 1995-01-11 Treatment of attention-deficit/hyperactivity disorder

Publications (1)

Publication Number Publication Date
ES2181845T3 true ES2181845T3 (es) 2003-03-01

Family

ID=23463572

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96300157T Expired - Lifetime ES2181845T3 (es) 1995-01-11 1996-01-09 Uso de tomoxetina para el tratamiento de la hiperactividad inducida por trastornos de la atencion.

Country Status (28)

Country Link
US (1) US5658590A (es)
EP (1) EP0721777B1 (es)
JP (2) JPH10512262A (es)
KR (1) KR19980701276A (es)
CN (2) CN1168095A (es)
AT (1) ATE222757T1 (es)
AU (1) AU688665B2 (es)
BR (1) BR9606903A (es)
CA (1) CA2209735C (es)
CZ (1) CZ292226B6 (es)
DE (2) DE122005000011I2 (es)
DK (1) DK0721777T3 (es)
ES (1) ES2181845T3 (es)
FI (1) FI119354B (es)
FR (1) FR10C0041I2 (es)
HU (1) HU227306B1 (es)
LU (1) LU91238I2 (es)
NL (1) NL300180I2 (es)
NO (2) NO317027B1 (es)
NZ (1) NZ301500A (es)
PL (1) PL187573B1 (es)
PT (1) PT721777E (es)
RO (1) RO118374B1 (es)
RU (1) RU2163802C2 (es)
SI (1) SI0721777T1 (es)
TR (1) TR199700627T1 (es)
UA (1) UA43385C2 (es)
WO (1) WO1996021430A1 (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
GB9613243D0 (en) * 1996-06-25 1996-08-28 Britannia Pharmaceuticals Ltd Attention deficit hyperactive disorder
UA57107C2 (uk) * 1997-09-23 2003-06-16 Елі Ліллі Енд Компані Спосіб лікування розладу поведінки
UA56257C2 (uk) * 1997-09-23 2003-05-15 Елі Ліллі Енд Компані Спосіб лікування неадекватної визивної поведінки
JP2001517628A (ja) * 1997-09-23 2001-10-09 イーライ・リリー・アンド・カンパニー 注意欠陥／多動障害の治療法
US5902797A (en) * 1997-11-10 1999-05-11 Beth Israel Deaconess Medical Center Nutritional supplement for use in the treatment of attention deficit
BR9909478A (pt) * 1998-04-09 2000-12-19 Upjohn Co Novos tratamentos para vários distúrbios do sistema nervoso
US6586427B2 (en) 1998-04-09 2003-07-01 Pharmacia & Upjohn Company Treatments for nervous disorders
ES2543819T3 (es) * 1998-11-09 2015-08-24 Biogen Inc. Tratamiento de neoplasias hematológicas asociadas con células tumorales circulantes utilizando anticuerpo quimérico dirigido contra CD20
US6419960B1 (en) 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
US6898455B2 (en) * 1999-10-29 2005-05-24 The Mclean Hospital Corporation Method for providing optimal drug dosage
US6400978B1 (en) 1999-10-29 2002-06-04 The Mclean Hospital Corporation Method and apparatus for detecting mental disorders
US6683114B2 (en) * 2000-03-07 2004-01-27 Eli Lilly And Company Treatment of psoriasis
US20020016334A1 (en) * 2000-07-31 2002-02-07 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD)
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US20040034106A1 (en) * 2001-11-06 2004-02-19 Read Holly Ann Treatment of anxiety disorders
CZ2004709A3 (cs) * 2001-12-11 2004-10-13 Eliálillyáandácompany Použití inbibitorů vychytávání norepinefrinu pro léčení poruch kognitivních funkcí
ATE413882T1 (de) 2002-08-23 2008-11-15 Lilly Co Eli 2-(phenylthiomethyl)- morpholin-derivate zur verwendung als selektive norepinephrin- wiederaufnahme-inhibitoren
GB0219687D0 (en) * 2002-08-23 2002-10-02 Lilly Co Eli Benzyl morpholine derivatives
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
WO2004103356A2 (en) * 2003-05-15 2004-12-02 Eli Lilly And Company Treatment of emotional dysregulation
ATE526954T1 (de) * 2003-07-28 2011-10-15 Leslie Joe Dunaway Atomoxetin zur behandlung von allergischer rhinitis und asthma
EP1660064A2 (en) * 2003-08-27 2006-05-31 Eli Lilly And Company Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors
WO2005020976A2 (en) * 2003-08-27 2005-03-10 Eli Lilly And Company Treatment of pervasive developmental disorders with norepinephrine reuptake inhibitors
ES2390879T3 (es) * 2003-12-31 2012-11-19 Actavis Group Ptc Ehf. Formulaciones de atomoxetina
US8545881B2 (en) 2004-04-19 2013-10-01 Eurand Pharmaceuticals, Ltd. Orally disintegrating tablets and methods of manufacture
EP1753430A2 (en) * 2004-05-27 2007-02-21 Warner-Lambert Company LLC Combination of atomoxetine and a 5ht1a receptor agonist for treating adhd and other disorders
US7439398B2 (en) * 2004-06-28 2008-10-21 Teva Pharmaceutical Fine Chemicals S.R.L. Enantiomerically pure atomoxetine and tomoxetine mandelate
US7439399B2 (en) * 2004-06-28 2008-10-21 Teva Pharmaceutical Fine Chemicals Processes for the preparation of atomoxetine hydrochloride
US7473804B2 (en) 2004-07-22 2009-01-06 Teva Pharmaceutical Fine Chemicals S.R.L. Polymorphs of atomoxetine hydrochloride
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
EP1802285B1 (en) 2004-10-21 2013-02-27 Aptalis Pharmatech, Inc. Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
EP1751085A1 (en) * 2005-04-05 2007-02-14 Teva Pharmaceutical Fine Chemicals S.R.L. Stable atomoxetine hydrochloride, a process for the preparation thereof, and an analytical control of its stability
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
US20070155820A1 (en) * 2005-11-23 2007-07-05 Auspex Pharmaceuticals, Inc. Substituted aryloxypropylamines with serotoninergic and/or norepinephrinergic activity
EP1963268B1 (en) 2005-12-07 2010-12-01 NSAB, Filial af NeuroSearch Sweden AB, Sverige Disubstituted phenylpiperidines as modulators of cortical catecholaminergic neurotransmission
US20080020387A1 (en) * 2006-03-31 2008-01-24 Lawrence Donald G Biomarker-optimized adhd treatment
US20080146675A1 (en) * 2006-04-05 2008-06-19 Eugenio Castelli Stable Atomoxetine Hydrochloride, a process for the preparation thereof, and an analytical control of its stability
US20080031932A1 (en) * 2006-08-04 2008-02-07 Watson Laboratories, Inc. Transdermal atomoxetine formulations and associated methods
US20080145318A1 (en) * 2006-12-13 2008-06-19 Midha Kamal K Atomoxetine formulations and associated methods
WO2008122019A1 (en) * 2007-04-02 2008-10-09 Cypress Biosciences, Inc. Improving the tolerability of both mirtazapine and reboxetine by using them in combination
ES2459322T3 (es) 2008-09-05 2014-05-09 Supernus Pharmaceuticals, Inc. Método de tratamiento de trastorno de déficit de atención con hiperactividad (TDAH)
RU2395313C2 (ru) * 2008-10-15 2010-07-27 Татьяна Прохоровна Тетерина Способ коррекции синдрома дефицита внимания и гиперактивности
TWI471146B (zh) 2009-12-02 2015-02-01 Aptalis Pharma Ltd 菲索特芬那定（ｆｅｘｏｆｅｎａｄｉｎｅ）微膠囊及包含其之組合物
US8927010B2 (en) 2011-03-23 2015-01-06 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
EP2688557B1 (en) 2011-03-23 2017-08-23 Ironshore Pharmaceuticals & Development, Inc. Methods and compositions for treatment of attention deficit disorder
US8916588B2 (en) 2011-03-23 2014-12-23 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
EP4233915A3 (en) 2012-02-08 2023-09-20 Supernus Pharmaceuticals, Inc. Modified release formulations of viloxazine
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
JP5973073B2 (ja) 2013-11-08 2016-08-23 イーライ リリー アンド カンパニー アトモキセチン溶液
CA2936741C (en) 2014-10-31 2018-11-06 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457121A (en) * 1994-09-02 1995-10-10 Eli Lilly And Company Cis-hexahydro-5-(1,2,3,4-tetrahydro-2-naphthalenyl)pyrrolo<3,4-c>pyrroles as inhibitors of serotonin reuptake
ZA958725B (en) * 1994-10-20 1997-04-16 Lilly Co Eli Treatment of disorders with duloxetine

Also Published As

Publication number Publication date
NO317027B1 (no) 2004-07-26
NZ301500A (en) 2000-07-28
PL187573B1 (pl) 2004-08-31
CN1168095A (zh) 1997-12-17
CA2209735C (en) 2002-10-01
US5658590A (en) 1997-08-19
RO118374B1 (ro) 2003-05-30
HUP9801283A2 (hu) 1999-06-28
NO2005006I2 (no) 2006-06-19
NL300180I2 (nl) 2005-08-01
PT721777E (pt) 2002-11-29
DE69623141T2 (de) 2003-04-24
NO973170D0 (no) 1997-07-08
KR19980701276A (ko) 1998-05-15
FR10C0041I1 (es) 2010-10-15
CN1781480A (zh) 2006-06-07
HU227306B1 (en) 2011-03-28
FI972922A (fi) 1997-07-09
DK0721777T3 (da) 2002-10-07
NO973170L (no) 1997-09-02
TR199700627T1 (xx) 1998-01-21
RU2163802C2 (ru) 2001-03-10
LU91238I2 (fr) 2006-07-03
FI972922A0 (fi) 1997-07-09
AU688665B2 (en) 1998-03-12
CZ292226B6 (cs) 2003-08-13
NL300180I1 (nl) 2005-05-02
EP0721777A2 (en) 1996-07-17
WO1996021430A1 (en) 1996-07-18
CA2209735A1 (en) 1996-07-18
CZ214597A3 (cs) 1998-01-14
AU4693896A (en) 1996-07-31
HUP9801283A3 (en) 1999-09-28
DE69623141D1 (de) 2002-10-02
DE122005000011I1 (de) 2005-06-23
UA43385C2 (uk) 2001-12-17
ATE222757T1 (de) 2002-09-15
MX9705117A (es) 1997-10-31
JP2005325139A (ja) 2005-11-24
SI0721777T1 (en) 2003-02-28
BR9606903A (pt) 1997-10-21
JPH10512262A (ja) 1998-11-24
EP0721777A3 (en) 1997-03-05
EP0721777B1 (en) 2002-08-28
PL321273A1 (en) 1997-11-24
FI119354B (fi) 2008-10-31
FR10C0041I2 (es) 2011-04-29
DE122005000011I2 (de) 2006-02-09

Similar Documents

Publication Publication Date Title
ES2181845T3 (es) Uso de tomoxetina para el tratamiento de la hiperactividad inducida por trastornos de la atencion.
BR0314603A (pt) Uso de inibidores da sìntese de citoquina para o tratamento de distúrbios de olhos secos
ES2163090T3 (es) Uso de toxina botulinica para tratar la cefalea tensional.
MX9300253A (es) Aparato manual para autoaplicarse la tecnica de acupresion.
PT971713E (pt) Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao
AR004321A1 (es) Empleo de epinastina para el tratamiento de dolores.
ES2166111T3 (es) Uso de tiagabina para el tratamiento de trastornos del sueño.
FI963070A (fi) Klooripyrimidiinivälituotteita
PT1143967E (pt) Utilizacao de derivados anticonvulsivos para o tratamento de cefaleias em salvas
BR0111358A (pt) Compostos de tioacetamida e seu uso
DOP2002000447A (es) 1-alquil o 1-cicloalquiltriazolo [4,3-a] quinazolin-5 onas como inhibidores de fosfodiesterasas
BR0111913A (pt) Análogos de gabapentina para distúrbios do sono
EA200200616A1 (ru) Химические производные и их применение в качестве антителомеразного агента
DE122009000036I1 (de) Verwendung von Dapoxetin, A selektiver Serotonin Aufnahme Inhibitor mit schnellem Wirkungseintritt, zur Behandlung von sexueller Disfunktion
BR9509006A (pt) Composiçao para aplicaçao tópica na pele composiçao farmacêutica uso de um inibidor de síntese de colesterol e processo para o tratamento mitigaçao ou prevençao de distúrbios de pele
BR0315644A (pt) Piperazinil e diazapanil benzamidas e benzotioamidas
BRPI0503445A (pt) composição cosmética não corante, uso de uma composição e processo para tratamento cosmético dos cabelos
BR0209541A (pt) Uso das imidazotriazinonas 2-fenil-substituìdas
AR021643A1 (es) Combinacion de cerivastatina y fibratos.
BR0209883A (pt) Uso de inibidores da proteasoma para o tratamento de distúrbios do olho seco
YU49422B (sh) Upotreba inhibitora ugljenične anhidraze za proizvodnju medikamenata za tretiranje makularnog edema ili makularne degeneracije izazvane starošću
EA199800152A1 (ru) Лечение синдрома дефицита внимания/гиперактивности
ES2134184T3 (es) Empleo de etisterona para el tratamiento topico del acne o de la alopecia androgenetica.
DE59900286D1 (de) Verwendung von sphingosin-1-phosphat, sphingosin-1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten
ES2182987T3 (es) Utilizacion de derivados de pirrolidina para el tratamiento del alcoholismo.